Feb 20, 2026 (MarketLine via COMTEX) --
Aspire Biopharma announced it received Nasdaq confirmation that it has regained compliance with the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1).
Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it had received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1). The Company announced on February 10, 2026 that it had received a letter from Nasdaq that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
The Company is now in full compliance with all Nasdaq continued listing requirements and the Company's common stock will remain listed and traded on the Nasdaq Stock Market.
Notwithstanding the compliance determination, the Company was also notified that it will remain subject to a "Panel Monitor," as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the Nasdaq notice, through February 18, 2027. If, during the term of the Panel Monitor, the Company does not continue to remain in compliance with the $2.5 million equity requirement, the Company will not be provided with the opportunity to submit a compliance plan for review by the Listing Qualifications Staff and must instead request a hearing before the Panel to address the deficiency, with such request staying any further action with respect to the Company's listing on Nasdaq pending completion of the hearing process.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
COMTEX_477841889/2227/2026-04-23T22:18:56
Copyright (C) 2026 Datamonitor. All rights reserved
